In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Featured article: Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
Protein measurements, alongside genetic mutations and gene expression assays, have long been used to study the heterogeneity of cancer data, specifically in Acute Myeloid Leukemia, which is not just one disease but a collection of molecularly distinct diseases. In this work we find that global proteomics can be even more useful that subtyping and can accurately predict drug response using our ex vivo drug assay across a small cohort of AML patients. We believe this type of analysis will help bring proteomics more closely aligned with the clinic as we can identify proteins that predict drug response in patient samples.
Make a suggestion here
Aims and scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Clinical translation of targeted proteomics
Guest edited by Tiannan Guo, Ed Nice, Stephen Pennington, Henry Rodriguez
Recent advancements in new analytical methods and techniques over the last decade, specifically mass spectrometry (MS)-based targeted proteomic analytical methods and techniques, now allow for the highly reproducible and precise measurement of nearly every human protein. We invite submissions for this special issue that focuses on the clinical translation of targeted MS proteomics and associated technologies.
Clinical Proteomics is affiliated with the Human Proteome Organization (HUPO). HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
38 days to first decision for all manuscripts (Median)
50 days to first decision for reviewed manuscripts only (Median)
258,084 Downloads (2021)
133 Altmetric mentions (2021)